What our clients say
Engaging Ichor has enabled us to variablize the fixed costs of operating a lab and dedicate our capital to scientific work. Ichor’s responsiveness and thoroughness are unmatched. We rely on their strategic guidance and competent experimental work; truly a partner rather than merely a vendor.
Ichor’s executive team has a unique talent for creative problem-solving and a goal-oriented approach to research. They have built and led several highly effective research initiatives for SENS Research Foundation, with a consistent focus on value creation and actionable endpoints.
Ichor has redefined effective implementation and quality assurance since I began working with them in 2014. Their emphasis on understanding project requirements, coupled with rigorous method development, elevate them head and shoulders above other CROs in the space.
See original video here. LAFAYETTE, N.Y. (WSYR-TV) – A small biotech company in Central New York is getting a big shot in the arm from some British investors. Ichor Therapeutics is operating its high tech lab out of an office in LaFayette. The company has just received a $10 million investment from Juvenescence, which has offices […]
Read the original article here. July 12, 2018 LAFAYETTE, N.Y.–(BUSINESS WIRE)–Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence […]
LaFayette, NY – Today the Longevity Research Institute, a non-profit organization that designs and funds animal studies to validate the anti-aging effects of promising compounds, announced the initiation of its first lifespan study, which will be conducted at Ichor Therapeutics. There are over 50 compounds and treatment regimens that have been reported to extend lifespan […]
Syracuse, NY – Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally […]